Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Rein Therapeutics (NASDAQ:RNTX) had its "hold" rating reaffirmed by analysts at Brookline Capital Management.
Rein Therapeutics (NASDAQ:RNTX) was downgraded by analysts at Citigroup Inc. to a "hold" rating.
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis